What you need to know about the new Malaria Treatment Medication

By MEGHAN SCHULTZThe new Malaria Treatment Medications is one of the most anticipated medical treatments of the year.

In 2016, more than 100 million people around the world were diagnosed with malaria.

With this year’s new treatment, many more people will be treated.

It’s a new drug that was developed by the National Institutes of Health, but it’s not the only one being developed.

There are a few other new medicines being developed that will be released over the next year or two, as well.

The first of these is a drug called Natalizumab.

This drug was originally developed by Pfizer and was first licensed in 2013.

The company is now making a larger version, which was approved in 2018.

It is designed to treat a more severe form of malaria, known as toxoplasmosis, and will be used in some African countries for the first time.

It has a wide range of side effects.

It’s not just one drug that’s going to be a lifesaver.

The drug is going to have side effects in addition to the side effects it’s supposed to be treating.

It can cause severe side effects such as fever, weakness, seizures, and bleeding.

And it’s also associated with a higher risk of dying.

The side effects include severe liver damage, blood clots, and a rare condition known as septicemia.

The drug has also been associated with several side effects, including a risk of death.

But Nataliseab can still treat more severe cases of malaria.

In addition, there are also new side effects associated with the drug, such as a more difficult time getting treatment.

This is because it is a newer drug, and so is not as safe as other treatments that have been on the market for years.

The risk of side-effects may not be as high, but they still exist.

The new drug is one part of Pfizer’s efforts to address the problems of the company.

Pfizer says it will continue to develop new and more effective drugs, even as the company’s business slows.

But it will not be the only new medicine being developed this year.

Pfizers drug is also the first to be released on the open market.

This new drug, called Nantucket’s B, has been approved by the Food and Drug Administration.

This medication is intended to treat people with the rare parasitic infection, toxoplasma gondii.

The medication has a slightly different form of treatment, which is called ritonavir, and it has been found to be effective in a study of adults in the United States.

Nantucket B is a smaller version of Pfizers new drug called Ritalin, which has been given to about 1.4 million adults with toxoplasias.

But the company said this is the first drug in the Ritaline family to be approved by FDA.

Ritalin is the drug that Pfizer said it is releasing to the public this year, but in addition, it is also being tested for its effectiveness in the treatment of toxoplasms in children and adults.

It will also be made available to some countries that have not had access to Pfizer-developed drugs for toxoplastic diseases, such the United Kingdom, Germany, and Switzerland.

This is the new drug Pfizer is making available to the general public, and in the past it has had mixed results.

In the past, the drug was more effective than the drugs Pfizer was selling for other diseases, and some patients said that the drugs were too expensive for their needs.

However, these trials have been very positive.

Pfizitres drug was initially found to have a milder side effect than the drug Pfizers drugs were selling for toxo.

And some of the adverse events have been much less severe.

The new drug has been able to treat some of these side effects and is currently available in some countries.

For Pfizer, this drug has the potential to be one of its biggest success stories in the last few years.

It has the power to transform the lives of millions of people around an entire continent.

In fact, Pfizer announced this week that it will be releasing another drug, Pfizil, in 2019, which could help to reverse the declining numbers of toxo cases.

This could be an opportunity for Pfizer to regain some of its market share.

But it is still not clear whether Pfizer will continue developing new and effective medicines, or whether it will find a way to use the new drugs to help it recover from the challenges of the past few years of setbacks.